Skip to main content
رجوع
CBIO logo

Crescent Biopharma, Inc.

جودة البيانات: 100%
CBIO
NASDAQ Healthcare Biotechnology
CEO: Joshua T. Brumm Employees: 41 IPO: Jan 10, 2014
السعر
KWD 18.37
التغيير
▲ KWD 1.75
10.53%
القيمة السوقية
506.22M
نطاق اليوم
KWD 17.00 KWD 18.43
نطاق 52 أسبوعًا
KWD 8.72 KWD 29.00
حجم التداول
199,217
متوسط 50 يوم / 200 يوم
KWD 11.37
KWD 12.68
الإغلاق السابق
KWD 16.62

Quick Summary

النقاط الرئيسية

Revenue grew 74.87% annually over 5 years — strong growth
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -72.45M
PEG of 0.07 suggests growth is underpriced
Capital efficient — spends only 8.47% of revenue on capex

النمو

Revenue Growth (5Y)
74.87%
أعلى من متوسط القطاع (9.58%)
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-143.95%
أقل من متوسط القطاع (3.68%)
ROIC-55.93%
Net Margin-1382.72%
Op. Margin-1407.52%

الأمان

Debt / Equity
0.01
أقل من متوسط القطاع (0.24)
Current Ratio6.56
Interest Coverage-69.85

التقييم

P/E Ratio
-3.38
أقل من متوسط القطاع (0.23)
Forward P/EN/A
P/B Ratio2.49
EV/EBITDAN/A
Dividend Yield0.00%

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (635 نظير)

المقياس السهم وسيط القطاع
P/E -3.4 0.2
P/B 2.5 2.9
ROE % -144.0 3.7
Net Margin % -1382.7 3.9
Rev Growth 5Y % 74.9 9.6
D/E 0.0 0.2

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) 3193.02%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 74.87% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10.84M Net Income (TTM) -149.94M
ROE -143.95% ROA -62.40%
Gross Margin 99.23% Operating Margin -1407.52%
Net Margin -1382.72% Free Cash Flow (TTM) -72.45M
ROIC -55.93% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 6.56
Interest Coverage -69.85
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.38 Forward P/E N/A
P/B Ratio 2.49 P/S Ratio 46.68
PEG Ratio 0.07 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -14.31%
Market Cap 506.22M Enterprise Value 294.67M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 10.84M 0.0 10,000.0 75,000.0 1.16M
Net Income -149.94M -71.47M -36.90M -46.69M -63.43M
EPS (Diluted) 0.02 -0.59 -0.58 -0.89 -1.23
Gross Profit 10.76M -35,174.0 10,000.0 75,000.0 1.16M
Operating Income -152.63M -68.76M -39.28M -47.40M -63.45M
EBITDA -149.67M 0.0 -39.12M -47.20M -63.18M
R&D Expenses 138.09M 56.14M 20.07M 28.39M 47.49M
SG&A Expenses 25.39M 12.63M 19.21M 19.09M 17.12M
D&A 84,000.0 68.76M 153,301.0 207,145.0 264,600.0
Interest Expense 2.19M 0.0 0.0 0.0 0.0
Income Tax -2.00M 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 240.29M 35.62M 45.32M 51.81M 94.35M
Total Liabilities 37.28M 51.10M 6.90M 8.88M 12.74M
Shareholders' Equity 203.01M 5.31M 38.41M 42.93M 81.60M
Total Debt 1.64M 37.48M 808,402.0 918,555.0 1.92M
Cash & Equivalents 213.19M 34.77M 41.79M 47.87M 90.25M
Current Assets 236.66M 34.80M 43.79M 50.71M 90.79M
Current Liabilities 36.07M 9.61M 6.84M 8.88M 11.82M